Market news — every asset we track

WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today...

Aug 19Barchart.com

MNPR

Monopar: Licensing Agreement, Rolling NDA Submission Serve As Catalysts For ‘Strong Buy’

Aug 18Seeking Alpha

MNPR

Monopar downgraded to Neutral at Cantor (MNPR:NASDAQ)

Monopar Therapeutics (MNPR) stock dips as Cantor Fitzgerald downgrades the company to Neutral from Overweight on valuation after its recent rally. Read more here.

Aug 13Seeking Alpha

MNPR

Cantor downgrades Monopar stock on valuation after 90% rally

Aug 13Investing.com

MNPR

Monopar Therapeutics stock price target raised to $133 by BTIG

Aug 12Investing.com

MNPR

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today...

Aug 12Barchart.com

MNPR

H.C. Wainwright raises Monopar stock price target to $125 on NDA filing

Jul 23Investing.com

MNPR

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage...

Jul 22Barchart.com

MNPR

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage...

Jul 20Barchart.com